Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Miller

Physician Assistant Yukon, OK Physician Assistant

NPI 1003239245 CMS profile 10912471

11900 Nw Expressway, Yukon, OK 73099

Open in the dashboard

General payments

$7,738

470 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Miller of Yukon, OK is reported in the CMS Open Payments database as having received $7,738 across 470 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,585 78
2024 General $1,576 93
2023 General $1,400 88
2022 General $1,712 114
2021 General $1,464 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Miller
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lauren Miller were reported at $1,585. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lauren Miller Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,464 $132 $37–$438 $132
2022 $1,712 $155 $48–$522 $149
2023 $1,400 $167 $52–$557 $160
2024 $1,576 $178 $55–$600 $164
2025 $1,585 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $994 66 payments
  2. Pfizer Inc. $906 57 payments
  3. AbbVie, Inc. $867 55 payments
  4. Novo Nordisk Inc $812 63 payments
  5. AstraZeneca Pharmaceuticals LP $513 20 payments
  6. GlaxoSmithKline, LLC. $508 36 payments
  7. Otsuka America Pharmaceutical, Inc. $494 21 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $422 25 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $375 23 payments
  10. Astellas Pharma US Inc $304 18 payments
  11. Other $1,543 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,738 470 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $526 32 payments
  2. Ozempic $513 39 payments
  3. RYBELSUS $469 37 payments
  4. REXULTI $464 20 payments
  5. FARXIGA $428 15 payments
  6. JARDIANCE $416 31 payments
  7. TRELEGY ELLIPTA $388 29 payments
  8. Kerendia $375 23 payments
  9. ELIQUIS $361 26 payments
  10. QULIPTA $354 20 payments
  11. Other $6,771 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

693

Median for Physician Assistant: 241

Drug cost

$80,340

Median for Physician Assistant: $4,110

Branded share of claims

15.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 14 $29,463
Ozempic Semaglutide Brand 14 $26,029
Jardiance Empagliflozin Brand 11 $17,539
Atorvastatin Calcium Generic 80 $863
Levothyroxine Sodium Generic 77 $673
Amlodipine Besylate Generic 44 $541
Olmesartan Medoxomil Generic 17 $509
Albuterol Sulfate Hfa Albuterol Sulfate Brand 21 $479
Gabapentin Generic 12 $442
Omeprazole Generic 25 $433

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$9,904

Medicare's payments for the services billed

Medicare patients

67

Average age 71

Services billed

281

41 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 37%
Ischemic heart disease 36%
Diabetes 33%
Depression 31%
Heart failure 24%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $136
$136 14 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
Veozah
  • Astellas Pharma US Inc $115
$115 — —
JARDIANCE
  • Lilly USA, LLC $56
  • Boehringer Ingelheim Pharmaceuticals, Inc. $24
$80 11 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $55
  • Lundbeck LLC $19
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

470 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record